Murphy, NY

Andrew Murphy, Croton-On-Hudson, NY US

Patent application number	Description	Published
20140275489	APELIN FUSION PROTEINS AND USES THEREOF - The invention provides a fusion protein or polypeptide comprising an apelin peptide fused to a multimerizing component. The invention also provides a fusion protein or polypeptide comprising an apelin peptide fused to an Fc domain, a fragment of an Fc domain, or a variant of an Fc domain. Apelin Fc-fusion polypeptides are capable of binding to the apelin receptor (APLNR). Apelin Fc-fusion polypeptides are capable of activating the APLNR and have improved pharmacokinetic properties compared to apelin peptides that are not fused to an Fc or an Fc fragment. Apelin Fc-fusion polypeptides are useful in diseases and conditions related to cardiovascular function, diabetes, cancer, obesity and other apelin-related conditions.	09-18-2014
20150037339	ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF - The present invention provides antibodies that bind to Activin A and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Activin A with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders characterized by decreased muscle mass or strength, such as sarcopenia, cachexia, muscle injury, muscle wasting/atrophy, cancer, fibrosis, and weight loss. The antibodies of the invention are also useful in combination with GDF8 binding proteins for the treatment of diseases and disorders characterized by decreased muscle mass or strength. The antibodies of the invention are also useful for the prevention, treatment, or amelioration of disorders and diseases caused by, promoted by, exacerbated by, and/or aggravated by Activin A, such as renal fibrosis.	02-05-2015

Andrew J. Murphy, Croton-On-Hudoson, NY US

Patent application number	Description	Published
20120192300	Common Light Chain Mouse - A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making light chain variable regions in mice, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, are provided.	07-26-2012

Andrew J. Murphy, Croton-On-Hudosn, NY US

Patent application number	Description	Published
20140023637	Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	01-23-2014
20140056903	HUMAN ANTIBODIES TO GFR ALPHA 3 AND METHODS OF USE THEREOF - The present invention provides antibodies that bind to human GFRα3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GFRα3. The antibodies of the invention are useful for the treatment of diseases and disorders associated with one or more GFRα3 biological activities, including the treatment of acute or chronic pain conditions, or inflammatory conditions.	02-27-2014

Andrew J. Murphy, Croton-On-Hudson, NY US

Patent application number	Description	Published
20090055943	Methods of modifying eukaryotic cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	02-26-2009
20110059095	HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN PROTEASE-ACTIVATED RECEPTOR-2 - The present invention provides antibodies that bind to protease-activated receptor-2 (PAR-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PAR-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more PAR-2 biological activities, including the treatment of pain conditions, inflammatory conditions and gastrointestinal conditions.	03-10-2011
20110104799	Multifunctional Alleles - Nucleic acid constructs and methods for rendering modifications to a genome are provided, wherein the modifications comprise null alleles, conditional alleles and null alleles comprising COINs. Multifunctional alleles (MFA) are provided, as well as methods for making them, which afford the ability in a single targeting to introduce an allele that can be used to generate a null allele, a conditional allele, or an allele that is a null allele and that further includes a COIN. MFAs comprise pairs of cognate recombinase recognition sites, an actuating sequence and/or a drug selection cassette, and a nucleotide sequence of interest, and a COIN, wherein upon action of a recombinase a conditional allele with a COIN is formed. In a further embodiment, action of a second recombinase forms an allele that contains only a COIN in sense orientation. In a further embodiment, action by a third recombinase forms an allele that contains only the actuating sequence in sense orientation.	05-05-2011
20110145937	Mice That Make Heavy Chain Antibodies - Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion in an immunoglobulin constant region CH1 gene (optionally a deletion in a hinge region) of an IgG, IgA, IgD, and/or IgE, and wherein the mouse is capable of expressing a functional IgM. Genetically modified mice are described, including mice having a functional IgM gene and modified to have a deletion of a CH1 domain and a hinge region in a heavy chain constant domain that is not an IgM, e.g., in an IgG heavy chain constant domain. Genetically modified mice that make human variable/mouse constant chimeric heavy chain antibodies (antibodies that lack a light chain), fully mouse heavy chain antibodies, or fully human heavy chain antibodies are provided.	06-16-2011
20110154512	Humanized Fc gamma R Mice - Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcγR genes from the endogenous FcγR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided.	06-23-2011
20110195454	Common Light Chain Mouse - A genetically modified mouse is provided, wherein the mouse is incapable of rearranging and expressing an endogenous mouse immunoglobulin light chain variable sequence, wherein the mouse expresses only one or two human light chain variable domains encoded by human immunoglobulin sequences operably linked to the mouse kappa (κ) constant gene at the endogenous mouse κ locus, wherein the mouse expresses a reverse chimeric antibody having a light chain variable domain derived from one of only two human light chain variable region gene segments and a mouse κ constant domain, and a human heavy chain variable domain and a mouse heavy chain constant domain, from an endogenous mouse heavy chain locus. Bispecific epitope-binding proteins that are fully human are provided, comprising two different heavy chains that associate with an identical light chain that comprises a variable domain derived from one of two different human light chain variable region gene segments.	08-11-2011
20110200982	GENETICALLY MODIFIED MICE AND ENGRAFTMENT - A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/Il2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g.,	08-18-2011
20110256556	Humanized FcgR Mice - Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcγR genes from the endogenous FcγR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided.	10-20-2011
20110258710	Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	10-20-2011
20110283376	Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	11-17-2011
20110307966	Mice Expressing Human Voltage-Gated Sodium Channels - Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a humanization of an extracellular loop of an endogenous Na	12-15-2011
20120021409	Common Light Chain Mouse - A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making light chain variable regions in mice, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, are provided.	01-26-2012
20120070861	Human Lambda Light Chain Mice - Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human λ variable sequences, including human antibodies, are provided.	03-22-2012
20120073004	Hybrid Light Chain Mice - Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human λ variable sequences, including human antibodies, are provided.	03-22-2012
20120083000	Neuropeptide Release Assay For Sodium Channels - Methods and compositions for using genetically modified non-human animals are provided, wherein the genetic modification comprises a humanization of the one or more extracellular pore loops of a Na	04-05-2012
20120093824	METHODS FOR TREATING PRURITUS BY ADMINISTERING AN ANTIBODY THAT SPECIFICALLY BINDS HUMAN PAR2 - The present invention provides methods for treating pruritus by blocking human protease activated receptor-2 (PAR2) activity. The methods of the invention can be used to treat pruritus associated with atopic dermatitis, psoriasis, burn scarring, hypertrophic scarring, keloids, renal failure or hepatic failure. The methods of the invention include administering an antibody or antigen-binding fragment thereof that specifically binds human PAR2.	04-19-2012
20120096572	Mice That Make VL Binding Proteins - Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain V gene segments, D gene segments, and J gene segments with at least one light chain V gene segment and at least one light chain J gene segment. Mice that make binding proteins that comprise a light chain variable domain operably linked to a heavy chain constant region are provided. Binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Modified cells, embryos, and mice that encode sequences for making the binding proteins are provided.	04-19-2012
20120260357	Low Affinity FcgR Deficient Mice - Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcγR genes from the endogenous FcγR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided.	10-11-2012
20120322108	Adam6 Mice - Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.	12-20-2012
20130022996	GENETICALLY MODIFIED MICE AND ENGRAFTMENT - A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g.,	01-24-2013
20130024957	GENETICALLY MODIFIED MICE AND ENGRAFTMENT - A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g.,	01-24-2013
20130042330	HUMANIZED M-CSF MICE - Genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein are provided. Also provided are genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein that have been engrafted with human cells such as human hematopoietic cells, and methods for making such engrafted mice. These mice find use in a number of applications, such as in modeling human immune disease and pathogen infection; in in vivo screens for agents that modulate hematopoietic cell development and/or activity, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to hematopoietic cells; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on hematopoietic cells; in in vivo screens of human hematopoietic cells from an individual to predict the responsiveness of an individual to a disease therapy, etc.	02-14-2013
20130045492	Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain - A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided.	02-21-2013
20130096287	Restricted Immunoglobulin Heavy Chain Mice - Mice having a restricted immunoglobulin heavy chain locus are provided, wherein the locus is characterized by a single polymorphic human V	04-18-2013
20130109053	Genetically Modified T Cell Receptor Mice	05-02-2013
20130111616	Genetically Modified Major Histocompatibility Complex Mice	05-02-2013
20130111617	Genetically Modified Major Histocompatibility Complex Mice	05-02-2013
20130117873	HUMANIZED IL-6 AND IL-6 RECEPTOR - Mice that comprise a replacement of endogenous mouse IL-6 and/or IL-6 receptor genes are described, and methods for making and using the mice. Mice comprising a replacement at an endogenous IL-6Rα locus of mouse ectodomain-encoding sequence with human ectodomain-encoding sequence is provided. Mice comprising a human IL-6 gene under control of mouse IL-6 regulatory elements is also provided, including mice that have a replacement of mouse IL-6-encoding sequence with human IL-6-encoding sequence at an endogenous mouse IL-6 locus.	05-09-2013
20130130388	Methods of Modifying Eurakyotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	05-23-2013
20130137101	Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	05-30-2013
20130160153	Humanized Light Chain Mice - Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin λ light chain variable domain.	06-20-2013
20130171149	Anti-ANGPTL3 Antibodies and Uses Thereof - A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.	07-04-2013
20130185819	Genetically Modified Major Histocompatibility Complex Animals - The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized β2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.	07-18-2013
20130185820	Genetically Modified Major Histocompatibility Complex Animals - The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II α and β polypeptides), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.	07-18-2013
20130185821	Common Light Chain Mouse - A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided.	07-18-2013
20130198879	Humanized Universal Light Chain Mice - Mice, tissues, cells, and genetic material are provided that comprise a humanized heavy chain immunoglobulin locus, a humanized light chain locus that expresses a universal light chain, and a gene encoding an ADAM6 or ortholog or homolog or functional fragment thereof. Mice are provided that express humanized heavy chains comprising human variable domains, and that express humanized light chains comprising human variable domains wherein the light chains are derived from no more than one, or no more than two, light chain V and J or rearranged V/J sequences. Fertile male mice that express antibodies with universal light chains and humanized heavy chains are provided. Methods and compositions for making bispecific binding proteins are provided.	08-01-2013
20130198880	MICE EXPRESSING A LIMITED IMMUNOGLOBULIN LIGHT CHAIN REPERTOIRE - A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that present a choice of two human light chain variable gene segments such that the immunoglobulin light chains expresses by the mouse comprise one of the two human light chain variable gene segments. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided.	08-01-2013
20130210137	Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	08-15-2013
20130212719	Humanized Rodents that Express Heavy Chain Containing VL Domains - Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a rodent (e.g., a mouse), wherein the non-human animals rearrange human immunoglobulin light chain gene segments in the context of heavy chain constant regions and express immunoglobulin-like molecules comprising human immunoglobulin light chain variable domains fused to heavy chain constant domains that are cognate with human immunoglobulin light chain variable domains fused to light chain constant domains.	08-15-2013
20130243775	MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF - The present invention provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecules comprise a first antigen-binding domain that specifically binds a target molecule, and a second antigen-binding domain that specifically binds an internalizing effector protein. The multispecific antigen-binding molecules of the present invention can, in some embodiments, be bispecific antibodies that are capable of binding both a target molecule and an internalizing effector protein. In certain embodiments of the invention, the simultaneous binding of the target molecule and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention results in the attenuation of the activity of the target molecule to a greater extent than the binding of the target molecule alone. In other embodiments of the invention, the target molecule is a tumor associated antigen, and the simultaneous binding of the tumor associated antigen and the internalizing effector protein by the multispecific antigen-binding molecule of the present invention causes or facilitates the targeted killing of tumor cells.	09-19-2013
20130247234	Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same - A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of pH dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon. Methods of making non-human animals that express antibodies comprising a histidine-containing universal light chain are provided.	09-19-2013
20130247235	Mice That Produce Antigen-Binding Proteins With pH-Dependent Binding Characteristics - Genetically modified non-human animals are provided that comprise an immunoglobulin heavy chain locus comprising an unrearranged human heavy chain variable region nucleotide sequence comprising an addition of at least one histidine codon or a substitution of at least one endogenous non-histidine codon with a histidine codon. Compositions and methods for making the genetically modified non-human animals as described herein are provided. Non-human animals capable of expressing an antigen-binding protein characterized by pH-dependent antigen binding, enhanced recyclability and/or enhanced serum half-life are also provided.	09-19-2013
20130247236	Non-Human Animals Expressing pH-Sensitive Immunoglobulin Sequences - Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a hisidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more CDRs, in an N-terminal region, and or in a loop 4 region are also provided. Immunoglobulin variable domains comprising one or more histidines (e.g., histidine clusters) substituted for non-antigen-binding non-histidine residues. Non-human animals that are progeny of animals comprising modified heavy chain variable loci (V, D, J segments), modified light chain variable loci (V, J segments), and rearranged germline light chain genes (VJ sequences) are also provided. Non-human animals that make immunoglobulin domains that bind antigens in a pH-sensitive manner are provided.	09-19-2013
20130254911	ADAM6 MICE - Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.	09-26-2013
20130259876	Anti-HLA-B*27 Antibodies and Uses Thereof - The present invention provides antibodies and antigen-binding fragments thereof that specifically bind HLA-B*27 (also called HLA-B27). In certain embodiments, the antibodies of the invention bind soluble and/or cell surface-expressed forms of HLA-B*27. The antibodies of the present invention, in certain embodiments, inhibit HLA-B*27-mediated activation of T cells. Certain exemplary antibodies of the present invention exhibit enhanced binding to HLA-B*27 as compared to other HLA-B allelic variants (e.g., HLA-B*07). The present invention also provides anti-HLA-B*27 antibodies with pH-dependent binding characteristics (e.g., higher affinity binding at neutral pH than at acidic pH). The antibodies of the invention are useful for the treatment of diseases and disorders associated with HLA-B*27 expression, including ankylosing spondylitis and other spondyloarthropathies.	10-03-2013
20130295097	Human Antibodies to Fel d1 and Methods of Use Thereof - The present invention provides antibodies that bind to the cat allergen, Fel d1, compositions comprising the antibodies, nucleic acids encoding the antibodies and methods of use of the antibodies. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals. The antibodies of the invention may also be useful for diagnostic purposes to determine if a patient is allergic to the Fel d1 cat allergen.	11-07-2013
20130302836	COMMON LIGHT CHAIN MOUSE - A genetically modified mouse is provided, wherein the mouse is incapable of rearranging and expressing an endogenous mouse immunoglobulin light chain variable sequence, wherein the mouse expresses only one or two human light chain variable domains encoded by human immunoglobulin sequences operably linked to the mouse kappa (κ) constant gene at the endogenous mouse κ locus, wherein the mouse expresses a reverse chimeric antibody having a light chain variable domain derived from one of only two human light chain variable region gene segments and a mouse κ constant domain, and a human heavy chain variable domain and a mouse heavy chain constant domain, from an endogenous mouse heavy chain locus. Bispecific epitope-binding proteins that are fully human are provided, comprising two different heavy chains that associate with an identical light chain that comprises a variable domain derived from one of two different human light chain variable region gene segments.	11-14-2013
20130302899	MULTIFUNCTIONAL ALLELES - Nucleic acid constructs and methods for rendering modifications to a genome are provided, wherein the modifications comprise null alleles, conditional alleles and null alleles comprising COINs. Multifunctional alleles (MFA) are provided, as well as methods for making them, which afford the ability in a single targeting to introduce an allele that can be used to generate a null allele, a conditional allele, or an allele that is a null allele and that further includes a COIN. MFAs comprise pairs of cognate recombinase recognition sites, an actuating sequence and/or a drug selection cassette, and a nucleotide sequence of interest, and a COIN, wherein upon action of a recombinase a conditional allele with a COIN is formed. In a further embodiment, action of a second recombinase forms an allele that contains only a COIN in sense orientation. In a further embodiment, action by a third recombinase forms an allele that contains only the actuating sequence in sense orientation.	11-14-2013
20130323790	HUMAN LAMBDA LIGHT CHAIN MICE - Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human λ variable sequences, including human antibodies, are provided.	12-05-2013
20130323791	RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN MICE - Mice having a restricted immunoglobulin heavy chain locus are provided, wherein the locus is characterized by a single polymorphic human V	12-05-2013
20130326647	HUMAN LAMBDA LIGHT CHAIN MICE - Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human λ variable sequences, including human antibodies, are provided.	12-05-2013
20130333057	Humanized Non-Human Animals with Restricted Immunoglobulin Heavy Chain Loci - Mice, embryos, cells, and tissues having a restricted immunoglobulin heavy chain locus and an ectopic sequence encoding one or more ADAM6 proteins are provided. In various embodiments, mice are described that have humanized endogenous immunoglobulin heavy chain loci and are capable of expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof that is functional in a male mouse. Mice, embryos, cells, and tissues having an immunoglobulin heavy chain locus characterized by a single human V	12-12-2013
20130340104	Humanized IL-7 Rodents - Genetically modified non-human animals comprising a human or humanized interleukin-7 (IL-7) gene. Cells, embryos, and non-human animals comprising a human or humanized IL-7 gene. Rodents that express human or humanized IL-7 protein. Genetically modified mice that comprise a human or humanized IL-7-encoding gene in their germline, wherein the human or humanized IL-7-encoding gene is under control of endogenous mouse IL-7 regulatory sequences.	12-19-2013
20140013456	Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same - A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of pH dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence. Methods of making non-human animals that express antibodies comprising histidine residues encoded by histidine codons introduced into immunoglobulin light chain nucleotide sequences are provided.	01-09-2014
20140013457	Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	01-09-2014
20140017228	HUMANIZED LIGHT CHAIN MICE - Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin λ light chain variable domain.	01-16-2014
20140017229	Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	01-16-2014
20140017238	Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	01-16-2014
20140017781	Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	01-16-2014
20140017782	Methods for Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	01-16-2014
20140018522	Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	01-16-2014
20140020124	Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	01-16-2014
20140020125	Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	01-16-2014
20140033336	Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	01-30-2014
20140033337	Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	01-30-2014
20140041068	Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	02-06-2014
20140044730	ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS - The present invention provides antibodies and antigen-binding fragments thereof that specifically bind proprotein convertase subtilisin/kexin-9 (PCSK9) with greater affinity at neutral pH than at acidic pH. The antibodies of the invention may possess one or more amino acid changes as compared to antibodies that do not exhibit pH-dependent binding properties. For example, the present invention includes anti-PCSK9 antibodies which possess one or more histidine substitutions in one or more complementarity determining regions. The antibodies of the invention, with pH-dependent binding properties, remain in circulation and exhibit cholesterol lowering activity for prolonged periods of time in animal subjects as compared to anti-PCSK9 antibodies that do not exhibit pH-dependent binding properties. The antibodies of the invention are therefore useful for treating diseases and disorders related to elevated HDL cholesterol, wherein the antibodies of the invention can be administered to a patient at a lower dose and/or with less frequent dosing as compared to antibodies that do not exhibit pH-dependent binding properties.	02-13-2014
20140073010	Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	03-13-2014
20140082760	Non-Human Animals Expressing pH-Sensitive Immunoglobulin Sequences - Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a hisidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more CDRs, in an N-terminal region, and or in a loop 4 region are also provided. Immunoglobulin variable domains comprising one or more histidines (e.g., histidine clusters) substituted for non-antigen-binding non-histidine residues. Non-human animals that are progeny of animals comprising modified heavy chain variable loci (V, D, J segments), modified light chain variable loci (V, J segments), and rearranged germline light chain genes (VJ sequences) are also provided. Non-human animals that make immunoglobulin domains that bind antigens in a pH-sensitive manner are provided.	03-20-2014
20140090095	Genetically Modified Mice and Engraftment - A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/Il2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g.,	03-27-2014
20140130193	MICE THAT MAKE VL BINDING PROTEINS - Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain V gene segments, D gene segments, and J gene segments with at least one light chain V gene segment and at least one light chain J gene segment. Mice that make binding proteins that comprise a light chain variable domain operably linked to a heavy chain constant region are provided. Binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Modified cells, embryos, and mice that encode sequences for making the binding proteins are provided.	05-08-2014
20140130194	MICE THAT MAKE VL BINDING PROTEINS - Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain V gene segments, D gene segments, and J gene segments with at least one light chain V gene segment and at least one light chain J gene segment. Mice that make binding proteins that comprise a light chain variable domain operably linked to a heavy chain constant region are provided. Binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Modified cells, embryos, and mice that encode sequences for making the binding proteins are provided.	05-08-2014
20140134662	GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOF - Genetically modified non-human animals are provided that may be used to model human hematopoietic cell development, function, or disease. The genetically modified non-human animals comprise a nucleic acid encoding human IL-6 operably linked to an IL-6 promoter. In some instances, the genetically modified non-human animal expressing human IL-6 also expresses at least one of human M-CSF, human IL-3, human GM-CSF, human SIRPa or human TPO. In some instances, the genetically modified non-human animal is immunodeficient. In some such instances, the genetically modified non-human animal is engrafted with healthy or diseased human hematopoietic cells. Also provided are methods for using the subject genetically modified non-human animals in modeling human hematopoietic cell development, function, and/or disease, as well as reagents and kits thereof that find use in making the subject genetically modified non-human animals and/or practicing the subject methods.	05-15-2014
20140137275	HYBRID LIGHT CHAIN MICE - Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human λ variable sequences, including human antibodies, are provided.	05-15-2014
20140154701	HUMANIZED FC GAMMA R MICE - Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcγR genes from the endogenous FcγR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided.	06-05-2014
20140157445	LOW AFFINITY FCGR DEFICIENT MICE - Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcγR genes from the endogenous FcγR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided.	06-05-2014
20140178879	Compositions and Methods for Modifying Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.	06-26-2014
20140179903	High Affinity Human Antibodies to Human Protease-Activated Receptor 2 - The present invention provides antibodies that bind to protease-activated receptor-2 (PAR-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PAR-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more PAR-2 biological activities, including the treatment of pain conditions, inflammatory conditions and gastrointestinal conditions.	06-26-2014
20140213773	ADAM6 MICE - Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.	07-31-2014
20140221625	B CELL LINEAGE BASED IMMUNOGEN DESIGN WITH HUMANIZED ANIMALS - Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in B-cell-lineage immunogen design in vaccine development are provided, as are methods of carrying out such design.	08-07-2014
20140245466	HUMANIZED T CELL CO-RECEPTOR MICE - The invention provides genetically modified non-human animals that express chimeric human/non-human T cell co-receptor polypeptides (e.g., CD4, CD8α, CD8β), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same.	08-28-2014
20140245467	GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE - The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I and MHC II polypeptides and/or human or humanized β2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.	08-28-2014
20140245468	NON-HUMAN ANIMALS WITH MODIFIED IMMUNOGLOBULIN HEAVY CHAIN SEQUENCES - Non-human animals, e.g., mammals, e.g., mice or rats, are provided comprising an immunoglobulin heavy chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence. The rearranged human immunoglobulin heavy chain variable region nucleotide sequence may be operably linked to a heavy or light chain constant region nucleic acid sequence. Also described are genetically modified non-human animals comprising an immunoglobulin light chain locus comprising one or more but less than the wild type number of human immunoglobulin light chain variable region gene segments, which may be operably linked to a light chain constant region nucleic acid sequence. Also provided are methods for obtaining nucleic acid sequences that encode immunoglobulin light chain variable domains capable of binding an antigen in the absence of a heavy chain.	08-28-2014
20140271642	IL-33 ANTAGONISTS AND USES THEREOF - The present invention provides interleukin-33 (IL-33) antagonists comprising one or more IL-33-binding domains and one or more multimerizing domains and methods of using the same. According to certain embodiments of the invention, the IL-33-binding domains can comprise an IL-33-binding portion of an ST2 protein and/or an extracellular portion of an IL-1 RAcP protein. The IL-33 antagonists of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as infectious diseases, inflammatory diseases, allergic diseases and fibrotic diseases.	09-18-2014
20140271658	ANTI-IL-33 ANTIBODIES AND USES THEREOF - The present invention provides antibodies that bind to interleukin-33 (IL-33) and methods of using the same. The invention includes antibodies that inhibit or attenuate IL-33-mediated signaling. The antibodies of the invention may function to block the interaction between IL-33 and ST2. Alternatively, certain antibodies of the invention inhibit or attenuate IL-33-mediated signaling without blocking the IL-33/ST2 interaction. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human IL-33 with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as inflammatory diseases, or allergic diseases.	09-18-2014
20140289876	MICE THAT MAKE HEAVY CHAIN ANTIBODIES - Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion in an immunoglobulin constant region CH1 gene (optionally a deletion in a hinge region) of an IgG, IgA, IgD, and/or IgE, and wherein the mouse is capable of expressing a functional IgM. Genetically modified mice are described, including mice having a functional IgM gene and modified to have a deletion of a CH1 domain and a hinge region in a heavy chain constant domain that is not an IgM, e.g., in an IgG heavy chain constant domain. Genetically modified mice that make human variable/mouse constant chimeric heavy chain antibodies (antibodies that lack a light chain), fully mouse heavy chain antibodies, or fully human heavy chain antibodies are provided.	09-25-2014
20140329711	Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same - A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of pH dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon. Methods of making non-human animals that express antibodies comprising a histidine-containing universal light chain are provided.	11-06-2014
20140356372	Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitor - The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) antagonist such as an anti-IL-4Rα antibody.	12-04-2014
20150020224	NON-HUMAN ANIMALS WITH MODIFIED IMMUNOGLOBULIN HEAVY CHAIN SEQUENCES - Non-human animals, e.g., mammals, e.g., mice or rats, are provided comprising an immunoglobulin heavy chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence. The rearranged human immunoglobulin heavy chain variable region nucleotide sequence may be operably linked to a heavy or light chain constant region nucleic acid sequence. Also described are genetically modified non-human animals comprising an immunoglobulin light chain locus comprising one or more but less than the wild type number of human immunoglobulin light chain variable region gene segments, which may be operably linked to a light chain constant region nucleic acid sequence. Also provided are methods for obtaining nucleic acid sequences that encode immunoglobulin light chain variable domains capable of binding an antigen in the absence of a heavy chain.	01-15-2015
20150024412	Humanized FcgammaR Mice - Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcγR genes from the endogenous FcγR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided.	01-22-2015
20150040253	GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE - The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II α and β polypeptides), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.	02-05-2015
20150047061	Humanized M-CSF Mice - Genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein are provided. Also provided are genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein that have been engrafted with human cells such as human hematopoietic cells, and methods for making such engrafted mice. These mice find use in a number of applications, such as in modeling human immune disease and pathogen infection; in in vivo screens for agents that modulate hematopoietic cell development and/or activity, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to hematopoietic cells; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on hematopoietic cells; in in vivo screens of human hematopoietic cells from an individual to predict the responsiveness of an individual to a disease therapy, etc.	02-12-2015
20150059009	METHODS FOR MAKING FULLY HUMAN BISPECIFIC ANTIBODIES USING A COMMON LIGHT CHAIN - A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided.	02-26-2015
20150082469	HUMANIZED IL-7 RODENTS - Genetically modified non-human animals comprising a human or humanized interleukin-7 (IL-7) gene. Cells, embryos, and non-human animals comprising a human or humanized IL-7 gene. Rodents that express human or humanized IL-7 protein. Genetically modified mice that comprise a human or humanized IL-7-encoding gene in their germline, wherein the human or humanized IL-7-encoding gene is under control of endogenous mouse IL-7 regulatory sequences.	03-19-2015
20150089678	NON-HUMAN ANIMALS HAVING A HUMANIZED SIGNAL-REGULATORY PROTEIN GENE - Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a SIRPα gene. Genetically modified mice are described, including mice that express a human or humanized SIRPα protein from an endogenous SIRPα locus.	03-26-2015
20150089679	NON-HUMAN ANIMALS HAVING A HUMANIZED SIGNAL-REGULATORY PROTEIN GENE - Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a SIRPα gene. Genetically modified mice are described, including mice that express a human or humanized SIRPα protein from an endogenous SIRPα locus.	03-26-2015
20150089680	Human Lambda Light Chain Mice - Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human λ variable sequences, including human antibodies, are provided.	03-26-2015
20150106961	Humanized IL-15 Animals - Genetically modified non-human animals comprising a humanized interleukin-15 (IL-15) gene. Cells, embryos, and non-human animals comprising a human IL-15 gene. Rodents that express humanized or human IL-15 protein.	04-16-2015
20150110801	HUMAN ANTIBODIES TO GFR ALPHA 3 AND METHODS OF USE THEREOF - The present invention provides antibodies that bind to human GFRα3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GFRα3. The antibodies of the invention are useful for the treatment of diseases and disorders associated with one or more GFRα3 biological activities, including the treatment of acute or chronic pain conditions, or inflammatory conditions.	04-23-2015
20150119556	Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same - A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of pH dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence. Methods of making non-human animals that express antibodies comprising histidine residues encoded by histidine codons introduced into immunoglobulin light chain nucleotide sequences are provided.	04-30-2015

Andrew J.m. Murphy, Croton-On-Hudson, NY US

Patent application number	Description	Published
20080268475	YEAST CELLS EXPRESSING MODIFIED G PROTEINS AND METHODS OF USE THEREFOR - The present invention pertains to novel yeast cells which are useful for the expression of heterologous G protein coupled receptors. The yeast cells of the present invention can be used in screening assays which can be used to screen for modulators of G protein coupled receptors. Specifically, the invention provides novel yeast cells which express a heterologous G protein coupled receptor and mutant and/or chimeric G protein subunit molecules which serve to functionally integrate the heterologous into the pheromone signaling pathway of the yeast cell. The invention also provides for the expression of heterologous G protein coupled receptors which are functionally integrated into the yeast cell membrane using a yeast α factor leader sequence. Drug discovery assays using the subject yeast cells are also provided.	10-30-2008

Barbara Murphy, Pelham Manor, NY US

Patent application number	Description	Published
20150133378	METHOD FOR PREDICTING RISK OF EXPOSURE TO INTERSTITIAL FIBROSIS AND TUBULAR ATROPHY WITH CLUSTERIN - A method for identifying a kidney transplant recipient at an increased risk of developing interstitial fibrosis or tubular atrophy which comprises obtaining a post-transplant urine sample from the kidney transplant recipient; measuring the level of clusterin in the urine sample; comparing the level of clusterin in the patient sample to the level of clusterin in a control sample from the urine of a non-fibrotic kidney transplant recipient; diagnosing a kidney transplant recipient with a clusterin level that is significantly higher than the clusterin level in the control as being at an increased risk of developing interstitial fibrosis or tubular atrophy.	05-14-2015

Breana Therese Murphy, Brooklyn, NY US

Patent application number	Description	Published
20130292418	UNIVERSAL YOKE AND DISPENSING DEVICE FOR CANISTERS - A universal yoke for actuating an actuation head of a canister is provided. The universal yoke can include a plurality of support ribs, an actuating nub including a first triggering surface, and an actuating tab including a second triggering surface. The plurality of support ribs can be arranged to nest with a plurality of differently shaped top portions of canisters. Either one of the first triggering surface and the second triggering surface can be arranged to independently actuate an actuation head of a nested canister top portion when the canister is forced into contact with the universal yoke. The universal yoke can be implemented with a dispensing device capable of cradling various-sized canisters.	11-07-2013

Christopher Joseph Murphy, Lagrangeville, NY US

Patent application number	Description	Published
20130041764	Method and System for Dynamic Textual Ad Distribution Via Email - A system and method for providing dynamic pay-for-placement advertisements via graphics-enabled email that generates a display of advertisements when the email newsletter is opened so the advertisements displayed are based on rankings at the time the email is opened instead of when the email was generated and transmitted. In one embodiment, a graphical-content email having one or more embedded advertisement image references is provided to one or more email recipients. The advertisement image reference, in one embodiment, may include query string parameters indicating the context of the image reference and/or portion of the image reference (i.e., identifying the image reference as being part of a particular newsletter email), a position of the image reference in the email display, and the like. A URL reference also may be included with each advertisement image reference (.e.g., one URL for each advertisement portion of the image to be retrieved by the advertising image reference).	02-14-2013

Dave Murphy, Delevan, NY US

Patent application number	Description	Published
20100215456	Adjustable Cargo Securing System - An apparatus for securing cargo to a vehicle, and to tie-downs or sliders receivable in rails mounted to a bed, load deck, or other storage area of a vehicle, such as a pickup, sport utility vehicle, or trailer is described. A user may easily change, adjust or customize the tie-down locations to suit a desired application. The cargo securing system has a rail with a generally C-shaped cross section, the open end of the C-shape defining a slot which may run along the entire length of the rail. The C-shaped rail also defines a channel which may run along the entire length of the rail. A slider member may reside in the channel and include a foot or base portion and an integral elongate portion which may protrude through the slot in the rail. The slider member may include an integral tie-down location on the elongate portion.	08-26-2010

Deirdre Murphy, Montebello, NY US

Patent application number	Description	Published
20100011602	TEMPLATE FOR HANGING PICTURE FRAMES - A template for assisting in the hanging of framed objects a predetermined distance from one another in which openings are spaced so that either the location for mounting hardware can either be marked or mounting hardware can be installed through the openings. The template may be used to position and visualize installation of subsequent framed objects.	01-21-2010

Ellen Murphy, City Island, NY US

Patent application number	Description	Published
20090318358	COMPOSITIONS AND METHODS OF USE OF ORF 554 FROM BETA HEMOLYTIC STREPTOCOCCAL STRAINS - The present invention relates to compositions and methods of use comprising peptidyl-prolyl isomerase (PPI) polypeptides of group C and G streptococci and polynucleotides encoding same. The invention also relates to immunogenic compositions comprising the PPI polypeptides and polynucleotides, as well as antibodies and antibody fragments that bind the PPI polypeptides. In addition, the invention relates to methods of inducing an immune response in a subject against beta hemolytic streptococci using the immunogenic compositions, as well as conferring passive immunity by administering a therapeutic antibody or antibody fragment.	12-24-2009
20090318359	COMPOSITIONS AND METHODS OF USE OF ORF1358 FROM BETA-HEMOLYTIC STREPTOCOCCAL STRAINS - The present invention relates to polynucleotides encoding	12-24-2009
20110171263	COMPOSITIONS AND METHODS OF USE OF ORF-1358 FROM BETA-HEMOLYTIC STREPTOCOCCAL STRAINS - The present invention relates to polynucleotides encoding	07-14-2011
20110177960	Microarray for monitoring gene expression in multiple strains of Streptococcus pneumoniae - The present invention features an array capable of monitoring gene expression patterns of multiple strains of	07-21-2011
20120107327	IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENS - The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from	05-03-2012
20140017271	IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENS - The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from	01-16-2014
20150132336	IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENS - The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from	05-14-2015

Eugene Murphy, Newburgh, NY US

Patent application number	Description	Published
20110165257	COATED DRUG SPHEROIDS AND USES THEREOF FOR ELIMINATING OR REDUCING CONDITIONS SUCH AS EMESIS AND DIARRHEA - The present invention provides an oral pharmaceutical formulation comprising coated spheroids of a kinase inhibitor such as neratinib, which formulation is designed to reduce or eliminate side effects associated with existing oral formulations of kinase inhibitors.	07-07-2011
20140004203	COATED DRUG SPHEROIDS AND USES THEREOF FOR ELIMINATING OR REDUCING CONDITIONS SUCH AS EMESIS AND DIARRHEA	01-02-2014

Gene Arthur Murphy, Schoharie, NY US

Patent application number	Description	Published
20120156020	METHOD OF REPAIRING A TRANSITION PIECE OF A GAS TURBINE ENGINE - A method of weld repairing an air-cooled aft frame of a transition piece of a gas turbine engine. The transition piece has an interior surface coated with a ceramic coating. The aft frame has a surface with cooling holes therein and from which cracks have propagated. The method includes removing the transition piece from the engine and, without removing the ceramic coating or the aft frame from the transition piece, weld repairing the cracks by performing a laser beam welding technique that deposits a filler material on the surface but does not close the cooling holes in the surface. The surface of the aft frame can be machined to remove excess filler material prior to re-installing the transition piece in a gas turbine engine.	06-21-2012

Gerald J. Murphy, Poughkeepsie, NY US

Patent application number	Description	Published
20110085988	SWOLLEN SILICONE COMPOSITION, PROCESS OF PRODUCING SAME AND PRODUCTS THEREOF - There is provided herein, in one specific embodiment, silicone composition(s) comprising unique combination(s) of silicone polymer and alkyltrisiloxane(s) which can produce silicone composition(s) with lower solids content than silicone compositions that use other than alkyltrisiloxane(s); while still maintaining a desirable viscosity.	04-14-2011

Gerard J. Murphy, Portchester, NY US

Patent application number	Description	Published
20110054706	KITCHEN GUN SYSTEM - A kitchen gun system for dispensing edible liquid ingredients as required for cooking. The kitchen gun system includes a plurality of pumps, each having an inlet and an outlet. Packages of edible liquid ingredients are attached to the inlets of the pumps. The outlets of the pumps are connected to a plurality of manifold inputs of a manifold. A plurality of manifold outputs is connected to a hand-held dispensing gun. The dispensing gun has a plurality of control mechanisms corresponding to at least the plurality of inputs on the manifold. Selected edible liquid ingredients may be selectively dispensed from the dispensing gun when desired by operating the respective control mechanisms on the dispensing gun. The kitchen gun system is suitable for use in a kitchen in a commercial establishment and includes sources of highly concentrated liquid precursor for stock, cooking oils and wines, lemon juice, and other liquids. These liquids are pumped to a hand-held gun and, if necessary, mixed with water in a desired concentration while being dispensed as required.	03-03-2011

Gregory B. Murphy, Sands Point, NY US

Patent application number	Description	Published
20100330256	Calcium Fortification of Bread Dough - Calcium additives useful for fortifying baked goods, such as bread products, with calcium are disclosed. The calcium additives are particularly useful for fortifying leavened baked goods with calcium. Methods for preparing the calcium additives and using the calcium additives to fortify baked goods are also disclosed. Generally, the calcium additives comprise intimate admixtures calcium carbonate and an acid such as citric acid.	12-30-2010
20110123616	Calcium Carbonate Granulation - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.	05-26-2011
20120201877	Calcium Carbonate Granulation - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.	08-09-2012
20120201878	CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.	08-09-2012
20120201879	CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.	08-09-2012
20120201880	CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.	08-09-2012
20120201881	CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.	08-09-2012
20120201882	CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.	08-09-2012
20120207829	CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.	08-16-2012
20120207830	CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.	08-16-2012
20120207859	CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.	08-16-2012
20120213849	CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.	08-23-2012
20120263862	Calcium Fortification of Bread Dough - Calcium additives useful for fortifying baked goods, such as bread products, with calcium are disclosed. The calcium additives are particularly useful for fortifying leavened baked goods with calcium. Methods for preparing the calcium additives and using the calcium additives to fortify baked goods are also disclosed. Generally, the calcium additives comprise intimate admixtures calcium carbonate and an acid such as citric acid.	10-18-2012
20120301519	CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.	11-29-2012
20120301545	CALCIUM CARBONATE GRANULATION - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.	11-29-2012
20130142841	Calcium Carbonate Granulation - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.	06-06-2013
20130142842	Calcium Carbonate Granulation - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.	06-06-2013
20130142843	Calcium Carbonate Granulation - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.	06-06-2013
20130164389	Calcium Carbonate Granulation - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.	06-27-2013
20140106057	CALCIUM FORTIFICATION OF BREAD DOUGH - Calcium additives useful for fortifying baked goods, such as bread products, with calcium are disclosed. The calcium additives are particularly useful for fortifying leavened baked goods with calcium. Methods for preparing the calcium additives and using the calcium additives to fortify baked goods are also disclosed. Generally, the calcium additives comprise intimate admixtures calcium carbonate and an acid such as citric acid.	04-17-2014
20140127293	Calcium Carbonate Granulation - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.	05-08-2014

James Edward Murphy, Niskayuna, NY US

Patent application number	Description	Published
20110279011	COLOR STABLE PHOSPHORS - An LED lamp includes a light source configured to emit radiation with a peak intensity at a wavelength between about 250 nm and about 550 nm; and a phosphor composition configured to be radiationally coupled to the light source. The phosphor composition includes particles of a phosphor of formula I, said particles having a coating composition disposed on surfaces thereof;	11-17-2011
20130270482	RARE EARTH GARNET SCINTILLATOR AND METHOD OF MAKING SAME - A detector for detecting high-energy radiation is disclosed. The detector includes scintillating material with a garnet structure includes gadolinium, yttrium, cerium, gallium, and aluminum. The scintillating material is expressed as (Gd	10-17-2013
20140116079	METHOD AND SYSTEM FOR STORAGE OF PERISHABLE ITEMS - A method and system for storage of perishable items is provided. The system includes at least one enclosed compartment to store the perishable items. At least one of the walls of the enclosed compartment is detachable to allow movement of the perishable items in and out of the compartment. The system further includes a plurality of light emitting diodes (LEDs) that are disposed on one of the walls of the compartment. The LEDs include one or more blue LEDs that are coated with a layer of phosphor material. The LEDs are electrically coupled with a power source. The system further includes a control unit that is configured to control power supplied by the power source to the LEDs based on presence of the perishable items in the compartment.	05-01-2014
20140166887	SCINTILLATOR ARRAYS AND METHODS OF MAKING SCINTILLATOR ARRAYS - Scintillator arrays and methods of making scintillator arrays are provided. One scintillator array includes a scintillator substrate having a plurality of scintillators spaced apart by gaps within the scintillator substrate and a smoothing layer overlaying a surface of the scintillator substrate within the gaps. The smoothing layer includes an organically modified silicate. The scintillator array also includes an optical reflector layer overlaying a surface of the smoothing layer within the gaps.	06-19-2014
20140264418	COLOR STABLE RED-EMITTING PHOSPHORS - A process for synthesizing a color stable Mn	09-18-2014
20140268655	COLOR STABLE RED-EMITTING PHOSPHORS - A color stable Mn4+ doped phosphor of formula I,	09-18-2014
20140327023	PHOSPHOR ASSEMBLY FOR LIGHT EMITTING DEVICES - A method for fabricating a light emitting device is disclosed. The light emitting device includes a light emitting diode (LED). The method includes disposing a layered phosphor composite or a thick phosphor composite radiationally coupled to the LED to form a light emitting device. The layered phosphor composite includes a first phosphor layer including a yellow-emitting phosphor over a second phosphor layer including manganese-doped potassium fluorosilicate (PFS). The second phosphor layer is disposed closer to the LED. The mass of the PFS of this light emitting device is at least 15% less than mass of the PFS in a reference light emitting device that has the same color temperature as the above mentioned light emitting device, but includes a blend of PFS and the yellow emitting phosphor instead of a layered configuration or has a decreased thickness.	11-06-2014
20140327026	COLOR STABLE RED-EMITTING PHOSPHORS - A process for synthesizing a color stable Mn	11-06-2014
20150054400	PROCESSES FOR PREPARING COLOR STABLE MANGANESE-DOPED PHOSPHORS - Low-HF or HF-free processes for improving color stability of a Mn	02-26-2015
20150092912	SYSTEMS AND METHODS FOR FILTERING EMISSIONS FROM SCINTILLATORS - Systems and method for filtering emissions from scintillators are provided. One system includes a scintillator having a scintillator material portion formed from a base scintillator material. The scintillator also includes a photodetector and a filter portion, The filter portion includes a material blocking near-infrared (IR) emissions. The filter portion is disposed on a surface of one of the scintillator material portion or the photodetector, and wherein the scintillator material portion, the photodetector, and the filter portion are coupled together. The filter portion blocks the near-IR emissions from impinging on the photodetector.	04-02-2015
20150123153	LED PACKAGE WITH RED-EMITTING PHOSPHORS - A process for fabricating an LED lighting apparatus comprising a color stable Mn	05-07-2015

James Patrick Murphy, Corning, NY US

Patent application number	Description	Published
20090120133	PROCESS AND SYSTEM FOR FINING GLASS - A glass making process comprising a step of fining the molten glass in a fining vessel comprising a top wall portion not in direct contact with the molten glass, and a side wall portion in direct contact with the molten glass, wherein the top wall portion has a temperature T(top), the side wall portion has a temperature T(side), and T(top)−T(side)≦10° C., and a glass fining system. The invention is particularly useful for glass fining systems comprising a metal fining vessel made of precious metals such as Pt and/or Pt—Rh alloys.	05-14-2009
20090217709	Nickel-containing flanges for use in direct resistance heating of platinum-containing vessels	09-03-2009
20090272150	CORROSION-RESISTANT CRADLE AND CASTABLE MATERIALS FOR GLASS PRODUCTION - A cradle for a high-temperature fluid delivery system, comprising a shell including a base and two side walls defining a trough, wherein the shell comprises fused zirconia. Fused zirconia provides the high temperature creep-resistance, corrosion resistance and thermal insulation to supported delivery system. The cradle extends system life, increases product quality and reduces costs associated with failure of glass delivery system.	11-05-2009
20120312053	NICKEL-CONTAINING FLANGES FOR USE IN DIRECT RESISTANCE HEATING OF PLATINUM-CONTAINING VESSELS	12-13-2012
20130003492	Stirrers for minimizing erosion of refractory metal vessels in a glass making system - Stirring apparatuses for stirring molten glass are disclosed. The method includes stirring a molten glass with a stirrer comprising a layer containing at least about 50% iridium. An apparatus comprising an iridium-containing layer is also presented. In one embodiment, an apparatus for stirring molten glass includes a cylinder comprising a bore. A stirrer may be disposed in the bore. The stirrer may include a platinum or platinum alloy shaft coaxial with the cylinder. A plurality of impellers may project radially from the shaft into close proximity of a wall of the cylinder. Each impeller may include an arcuate distal end portion farthest from the shaft. The distal end portion of each impeller consists of iridium or an iridium alloy and the remainder of the impeller consists of platinum or a platinum alloy. The stirring apparatuses reduce metal loss from the refractory metal of the stirring apparatus.	01-03-2013
20140013806	APPARATUS FOR USE IN DIRECT RESISTANCE HEATING OF PLATINUM-CONTAINING VESSELS - An apparatus for use in controlling a temperature of an oblong-shaped molten glass-carrying vessel, such as a conduit for transporting the molten glass from one location to another location, by flowing a current through the vessel. The apparatus comprises a metal flange comprising a plurality of electrically-conductive rings that include an inner ring joined to the vessel's exterior wall and an outer ring surrounding the inner ring. The inner ring, for example, may include an outer perimeter that is substantially oblong. In some embodiments the inner ring comprises a notch that aids in making current density more uniform. In some examples the width of the inner ring, excluding the notch, does not substantially vary as a function of angular position relative to the vessel.	01-16-2014
20150107306	APPARATUS AND METHODS FOR PRODUCING GLASS RIBBON - An apparatus for producing glass ribbon comprises a melting vessel configured to melt a batch of material into a quantity of molten glass. The apparatus includes a cooling conduit with a peripheral wall comprising platinum and defining an interior pathway configured to provide a travel path for the quantity of molten glass traveling from the first conditioning station to the second conditioning station. The peripheral wall includes an outer surface defining a plurality of elongated radial peaks spaced apart by a plurality of elongated radial valleys. The elongated radial peaks and elongated radial valleys are helically wound along an elongated axis of the cooling conduit. In further examples, methods are provided with the step of passing molten glass through the interior pathway of the cooling conduit to pass the molten glass from the first conditioning station to the second conditioning station.	04-23-2015

Jane M. Murphy, Vestal, NY US

Patent application number	Description	Published
20080281657	System and method for assessing a procurement and accounts payable system - A system for deploying to a client accounting installation a general procurement and accounts payable application specifically configured for the client by an enterprise includes a database server for (1) maintaining on a storage device a database of templates describing procedures for assessing, preparing, developing, deploying and supporting the application, and for (2) serving these templates to team members operating web-enabled terminals for coordinating, recording and tracking team activities with respect to the application while generating a description for adapting a front end server and an accounting system server to the requirements of the client.	11-13-2008
20110276458	SYSTEM FOR MANAGING INTERNET TRADING NETWORKS - A system for performing a method for managing a supplier for participation in trading networks. The method includes: receiving from each trading network a volume commitment consolidating volume commitments for offerings of commodities and services; negotiating with each trading network to supply to customer members of the trading network the commodity or service; storing, for each trading network for each supplier, attributes including start date, end date, services and products offered to the trading network, and payment flow for the commodities and services; offing a trading network package based on negotiations occurring before receiving purchase requests from the customer members, the trading network package including: (i) a value-add service offering to the customer members for a fee, and (ii) a managed package for which a customer member provides a volume commitment and actual purchases are tracked; and negotiating price discount levels for committed levels of demand from the trading networks.	11-10-2011
20130006836	MANAGING TRADING IN TRADING NETWORKS - A method and system for managing trading in trading networks. At least one trading network package is offered. Each trading network package is based on negotiations occurring prior to receiving purchase requests from customer members of the trading network. Each trading network package is configured to include: (i) a value-add service offering offered by the trading network to the customer members for a fee, (ii) a managed package for which a customer member of the customer members provides a volume commitment and for which actual purchases are tracked; or (iii) both the value-add service offering and the managed package.	01-03-2013

Jeff Murphy, Lancaster, NY US

Patent application number	Description	Published
20120295796	System and Method of Predicting Chemical Interaction and Functionality of Molecules - A system and method of identifying a target molecule that bind to the bioactive site of a protein or protein complex is described. The system and method includes the steps of calculating the information signature of a first molecule that is known to bind to the bioactive site of a protein or protein complex, wherein the information signature is a string of numerical values based on the average distance and physico-chemical properties of each atom of a plurality of atoms in the first molecule, calculating the information signature of each target molecule in a library of target molecules, comparing the information signature of the first molecule to the information signatures of the target molecules, and selecting the target molecules having an information signature that is similar to the information signature of the first molecule.	11-22-2012

John T. Murphy, Niskayuna, NY US

Patent application number	Description	Published
20100218609	METHOD AND SYSTEM FOR ULTRASONIC INSPECTION OF GEARBOX RING GEAR - A method and system for ultrasonically inspecting a ring gear of a gearbox is provided. The method and system can be used for the detection, characterization and/or sizing of defects in the ring gear. The ring gear has a plurality of teeth, which extend radially inward with respect to an outer surface of the gearbox. The method includes the steps of selecting an ultrasonic transducer productive of a test signal, positioning the ultrasonic transducer at an outer surface of the ring gear, orienting the ultrasonic transducer so as to direct the test signal to propagate through the ring gear, and activating the ultrasonic transducer so as to test the ring gear for defects therein.	09-02-2010

John Thomas Murphy, Niskayuna, NY US

Patent application number	Description	Published
20120136630	METHOD AND SYSTEM FOR WIND TURBINE INSPECTION - A method and system for inspecting a wind turbine is provided. The method includes providing at least one remotely operated aerial platform (ROAP), providing at least one non-destructive evaluation (NDE) device attached to the ROAP, and providing at least one distance measuring system attached to the ROAP. The distance measuring system is used for determining the distance between the ROAP and at least a portion of the wind turbine. The method also includes positioning the ROAP so that the at least one non-destructive evaluation device captures data used for inspecting the wind turbine.	05-31-2012

Kevin Murphy, Manhasset, NY US

Patent application number	Description	Published
20150134355	POST PROCEDURE CARE AND WELLNESS MANAGEMENT - Systems and methods for post procedure care and wellness management. A care network for a care recipient in providing post procedure care to the care recipient for a procedure performed on the care recipient is formed. A user specific care plan for the care recipient is generated, the user specific care plan including post procedure content and first post procedure care conditions associated with the post procedure content is generated for the care recipient. Whether the first post procedure care conditions are satisfied is determined. The post procedure content is sent to the care recipient through an internal communication channel. A first care data received notification comprising a generic notification lacking any personal health information of the care recipient is sent to the care recipient through an external communication channel. The care recipient is logged in to view the post procedure content through the internal communication channel.	05-14-2015

Killian D. Murphy, Brooklyn, NY US

Patent application number	Description	Published
20090281770	PLATFORM MATCHING SYSTEMS AND METHODS - Pursuant to some embodiments, a platform matching system, method, apparatus and means are provided which include identifying at least a first benchmark test procedure to evaluate at least a first and a second target platform for use with an application, the at least first benchmark test procedure including at least a first unit test; receiving test result data from tests performed on the at least first and second target platform using the at least first benchmark test procedure; and performing a matching analysis to determine which of the at least first and second target platform is a best fit for the application.	11-12-2009
20130124145	PLATFORM MATCHING SYSTEMS AND METHODS - Pursuant to some embodiments, a platform matching system, method, apparatus and means are provided which include identifying at least a first benchmark test procedure to evaluate at least a first and a second target platform for use with an application, the at least first benchmark test procedure including at least a first unit test; receiving test result data from tests performed on the at least first and second target platform using the at least first benchmark test procedure; and performing a matching analysis to determine which of the at least first and second target platform is a best fit for the application.	05-16-2013

Liam C. Murphy, Lake Groove, NY US

Patent application number	Description	Published
20090102193	Fluid-driven electric generator for operatively connecting to a conduct carrying a fluid - A fluid-driven electric generator for operatively connecting to a conduit carrying a fluid. The generator includes a driving portion and a generating portion. The driving portion is non-protrudingly positioned in the conduit so as to have its placement be non-visible from outside the conduit and is activated by the fluid flowing in the conduit. The generating portion is operatively connected to the driving portion and generates electricity when the driving portion is activated by the fluid flowing in the conduit.	04-23-2009

Maureen Murphy, Brooklyn, NY US

Patent application number	Description	Published
20090119312	Taxonomy tool - In one general aspect, the present disclosure is directed to a system for describing information. This system may comprise at least one processor. The at least one processor may be configured to receive a taxonomy that may comprising a metric hierarchy and a plurality of entity hierarchies. The at least one processor may also be configured to display an indication of a metric selected from the metric hierarchy. In addition, the at least one processor may be configured to display a representation of at least a portion of a second hierarchy selected from the plurality of entity hierarchies. The representation may comprise an indication of a branch of the second hierarchy and an indication of a relationship between the branch of the second hierarchy and the metric.	05-07-2009

Michael John Murphy, Kenmore, NY US

Patent application number	Description	Published
20100036178	PROCESS FOR MAKING CHLOROTRIFLUOROETHYLENE FROM 1,1,2-TRICHLOROTRIFLUOROETHANE - A process for the making chlorotrifluoroethylene. The process has the step of reacting 1,1,2-trichlorotrifluoroethane with a reducing metal in the presence of a polar aprotic solvent under conditions sufficient to form chlorotrifluoroethylene.	02-11-2010
20100222616	Process for Making Chlorotrifluoroethylene from 1,1,2-Trichlorotrifluoroethane - Disclosed is a process for the making chlorotrifluoroethylene. The process comprises the step of reacting 1,1,2-trichlorotrifluoroethane with a reducing metal in the presence of a polar aprotic solvent under conditions sufficient to form chlorotrifluoroethylene.	09-02-2010

Michael S. Murphy, Baldwinsville, NY US

Patent application number	Description	Published
20090212269	CONFIGURABLE WINCH - A lift system having a modular backbone with two or more backbone sections being attached end to end to form the backbone. Also, a lift system with end to end modular attachment, using universal joints, between motor assembly(ies), shaft section(s), drum assembly(ies) and/or shaft end sections. Also, a lift assembly with a backbone having longitudinally adjustable lift component attachment hardware, such as an elongated slot with lips suitable for engaging a nut tooth.	08-27-2009
20090242861	POWER CABLE - A winch system with a force cable that transmits electrical current and/or digital data to the load. For example, the force cable, including a power line and/or a signal line and includes at least: (i) a first portion extending from the load to the drum; and (ii) a second portion that is wound around the drum. If there is a power line in the force cable it is electrically connected to an electrical commutator by a rotating current path. If there is a signal line in the force cable it is connected in data communication to a data signal commutator by a rotating communication path. The commutator also has an input for receiving electrical current and/or digital data, as appropriate. The commutator transmits the electrical current and/or digital data from its input to the rotating current path and/or communication path. The drum defines an axial channel extending from at least one end of the drum along its axial direction, and current path(s) and/or communication path(s) are routed through the channel. There is a distribution box at a first axial end of the drum and the commutator is at the second axial end of the drum. The drum includes at least one radial channel that includes: (i) a first portion for receiving a force bearing member of the force cable from outside of the drum; and (ii) a second portion for guiding at least a portion of the current path(s) and/or the communication path(s) from outside of the drum to the axial channel.	10-01-2009
20120138244	Chain Drive System For Use In A Theatre - A system for suspending a vertical curtain (especially a theatrical curtain) and for driving the curtain to move horizontally (for example, between a position covering a stage and a position not covering a stage). The curtain is suspended directly from a drive chain, along at least a portion of the drive chain, by chain attachment structures. Also, a rotating switch that can be actuated by a switch attachment structure supported by the drive chain. Also, the use of a dedicated encoder sprocket which is separate from the guide sprockets.	06-07-2012
20120173408	Donor Locking Rail - A system and/or method for recognizing a theatre donation by placing a notice on a locking rail sub-system in a theatre. This system and/or method is believed to be rather counterintuitive because the locking rail is generally a low visibility part of the theatre, where the general public does not traditionally go. Despite this low visibility, the present invention is believed to foster a surprisingly large amount of goodwill, the relatively low visibility of the locking rail assembly notwithstanding. Also, because the locking rail is such a critical piece of equipment for safety purposes, the present invention recognizes that the good associations with donors and/or donations will tend to be subtly and psychologically enhanced by the fact that the donation related information is placed on the locking rail assembly. Also disclosed is a video display (for example, an LCD video display) that is mechanically connected to the rail of a locking rail assembly, and is used to convey information relating to the locking rail assembly.	07-05-2012

Michael W. Murphy, Manchester, NY US

Patent application number	Description	Published
20080233443	Fuel Cell Control Valve - A flow control valve for a fuel cell that has particular application for controlling the flow of cathode air through a cathode flow channel of the fuel cell. The valve includes an element that controls the flow through the flow channel in response to changes in the voltage potential of the fuel cell. The valve includes a shape memory alloy wire and a flow control element secured to both ends of the shape memory alloy wire. The ends of the wire are also coupled to the anode and cathode of the fuel cell. When no current is flowing through the wire, the flow control element holds the wire in a pre-strained condition. If the voltage generated by the fuel cell increases, the current passing through the wire will heat the wire and cause it to shrink or contract which forces the flow control element into the flow path.	09-25-2008

Michael William Murphy, Palmyra, NY US

Patent application number	Description	Published
20110304555	Novel Character Specification System and Method that Uses a Limited Number of Selection Keys - A method and apparatus of identifying and selecting characters from among a plurality of characters. In accordance with one embodiment of the invention, a computer processor electronically enables identification of each of a plurality of characters arranged in a one-dimensional array. Each character is identified by an integer value that corresponds to the number of positions the character is offset from a reference position of the one-dimensional array. The computer processor electronically enables selection of any of the characters by receiving input resulting from activation of selection keys that specify the integer value of a character desired for selection. In one further embodiment, each selection key has an assigned integer value, and the integer value that identifies the selected character is calculated by summing the assigned integer values of each selection key activated for each instance that each selection key is activated within a selectable-length time period.	12-15-2011

Monica F. Murphy, New York, NY US

Patent application number	Description	Published
20090282702	STABILIZING AND SUPPORT ACCESSORY FOR STILETTO HEELS - A slip-on, slip-off stabilizing support accessory for a stiletto heel. The device is a unitary molding of semi-rigid, resilient plastic material formed with a generally hourglass configuration, with outwardly concave, resiliently flexible side walls for frictionally engaging opposite sides of a stiletto heel. An outwardly flared top opening facilitates application of the device to the heel, while an outwardly flaring bottom configuration provides a greatly enlarged ground contact area. Front and back edges of the side walls are of outwardly concave shape. Front and back wall structures, formed by relatively narrow, spaced-apart elements, enable the side walls to be flexed for easy application to heels of various sizes, while firmly gripping heels of the smallest size.	11-19-2009

Patricia Murphy, Long Beach, NY US

Patent application number	Description	Published
20130031717	SHOWER LINER SYSTEM AND METHOD - The system of the present application is directed towards a shower liner system including a plurality of layers, each of the plurality of layers including a top portion, the top portion of each of the plurality of layers having a plurality of attachment points, a bottom portion and a line of perforation separating the top portion and the bottom portion, wherein a bottom portion of each of the plurality of layers can be removed without removing the top portion, and wherein the upper portion of each of the plurality of layers are fastened together. The method of the present application is directed towards a method of using a shower liner system.	02-07-2013

Patricia D. Murphy, Slingerlands, NY US

Patent application number	Description	Published
20090269814	Method of Analyzing a BRCA2 Gene in a Human Subject - Five novel DNA and protein sequences have been determined for the BRCA2 gene, as have been ten polymorphic sites and their rates of occurrence in the normal alleles of BRCA2. The sequences BRCA2	10-29-2009
20090325237	Method of Analyzing a BRCA2 Gene in a Human Subject - Five novel DNA and protein sequences have been determined for the BRCA2 gene, as have been ten polymorphic sites and their rates of occurrence in the normal alleles of BRCA2. The sequences BRCA2	12-31-2009
20090325238	Method of Analyzing a BRCA2 Gene in a Human Subject - Five novel DNA and protein sequences have been determined for the BRCA2 gene, as have been ten polymorphic sites and their rates of occurrence in the normal alleles of BRCA2. The sequences BRCA2	12-31-2009
20130280703	METHOD OF ANALYZING A BRCA2 GENE IN A HUMAN SUBJECT - Five novel DNA and protein sequences have been determined for the BRCA2 gene, as have been ten polymorphic sites and their rates of occurrence in the normal alleles of BRCA2. The sequences BRCA2	10-24-2013
20140302494	METHOD OF ANALYZING A BRCA2 GENE IN A HUMAN SUBJECT - Five novel DNA and protein sequences have been determined for the BRCA2 gene, as have been ten polymorphic sites and their rates of occurrence in the normal alleles of BRCA2. The sequences BRCA2	10-09-2014

Patrick J. Murphy, Marcellus, NY US

Patent application number	Description	Published
20110115511	ELECTRICAL DEVICE WITH MISWIRE PROTECTION AND AUTOMATED TESTING - The present invention is directed to an electrical wiring device that includes an actuator assembly that is responsive to the fault detection signal. The actuator assembly includes a breaker coil configured to generate an actuation force in response to being energized. A circuit interrupter includes four sets of movable contacts configured to be driven into a reset state in response to a reset stimulus, the four sets of movable contacts being configured to be driven into a tripped state in response to the actuation force. A self-test circuit is coupled to the plurality of line terminals or the at least one sensor. The self-test circuit is configured to automatically generate a test signal from time to time during a predetermined portion of an AC power line cycle. The self-test circuit is configured such that the test signal is sensed by the at least one sensor when the at least one sensor is operational, the sensor output signal being a function of the test signal. A monitor circuit is configured to monitor the fault detection circuit or the actuator assembly; the mechanical actuation force is substantially inhibited when the fault detection circuit or at least a portion of the actuator assembly properly respond to the test signal. The monitor circuit generates an end-of-life response if the fault detection circuit or the actuator assembly do not respond to the test signal within a predetermined period of time.	05-19-2011
20110261490	PROTECTION DEVICE WITH A SANDWICHED CANTILEVER BREAKER MECHANISM - The present invention is directed to a protective electrical wiring device that includes a housing assembly having a plurality of receptacle terminals comprising hot user-accessible terminal structure and a neutral user-accessible terminal structure accessible via at least one user-accessible receptacle. A circuit interrupting assembly is coupled to a fault detection circuit. The circuit interrupting assembly is configured to establish electrical continuity between the plurality of line terminals, the plurality of load terminals and the plurality of receptacle terminals in a reset state and interrupt the electrical continuity in a tripped state. The circuit interrupting assembly includes at least one first circuit interrupter member and at least one second circuit interrupter member, the at least one first circuit interrupter member being configured to drive the at least one second circuit interrupter member into the reset state in response to a make force. The at least one first circuit interrupter member and the at least one second circuit interrupter member are counter-driven into the tripped state by a break force. At least one stop member is disposed in a substantially fixed position relative to the housing assembly. The at least one stop member is configured to limit the movement of the at least one second circuit interrupter member such that a gap between the at least one first circuit interrupter member and the at least one second circuit interrupter member is substantially equal to a predetermined distance in the tripped state.	10-27-2011
20120188668	PROTECTION DEVICE WITH A SANDWICHED CANTILEVER BREAKER MECHANISM - The present invention is directed to a protective electrical wiring device that includes a circuit assembly that has a fault detection circuit coupled to the plurality of line terminals, the fault detection circuit being configured to detect perturbations corresponding to a fault condition or a simulated fault condition, the fault detection circuit being configured to provide a fault detection signal in response to detecting the perturbations corresponding to the fault condition or the simulated fault condition. An interrupting contact assembly is coupled to the fault detection circuit, the interrupting contact assembly including a contact assembly configured to provide electrical continuity between the plurality of line terminals, the plurality of feed-through load terminals, and the plurality of receptacle load terminals in a reset state, and interrupt the electrical continuity in a tripped state in response to the fault detection signal, the contact assembly including a hot contact mechanism and a neutral contact mechanism configured to move in unison between the reset state and the tripped state, the hot contact mechanism including a first hot contact disposed at an end portion of a first hot arm, a second hot contact disposed at an end portion of a second hot arm, and a third hot contact disposed at an end portion of a third hot arm, the neutral contact mechanism including a first neutral contact disposed at an end portion of a first neutral arm, a second neutral contact disposed at an end portion of a second neutral arm, and a third neutral contact disposed at an end portion of a third neutral arm.	07-26-2012
20130057990	ELECTRICAL DEVICE WITH MISWIRE PROTECTION AND AUTOMATED TESTING - The present invention is directed to an electrical wiring device that includes a plurality of line terminals configured to be coupled to a source of AC power, a plurality of feed-through load terminals, and at least one set of receptacle load terminals configured to provide the AC power to a user load via an AC power plug. A circuit interrupter assembly includes a plurality of movable interconnection members. Each movable interconnection member includes a first interconnecting contact disposed on a first side thereof and a second interconnecting contact disposed on a second side thereof. The first interconnecting contact and the second interconnecting contact are offset from one another in a direction substantially orthogonal to a direction of movement. The movable interconnection members are movable in the direction of movement between a reset position wherein the plurality of line terminals, the plurality of feed-through load terminals and the at least one set of receptacle load terminals are electrically connected, and a tripped position wherein the plurality of line terminals, the plurality of feed-through load terminals and the at least one set of receptacle load terminals are electrically disconnected.	03-07-2013
20130250459	PROTECTION DEVICE WITH A SANDWICHED CANTILEVER BREAKER MECHANISM - The present invention is directed to a protective electrical wiring device that includes at least one first stop member disposed proximate at least one first conductor. The at least one first stop member is configured to limit the movement of the at least one first conductor when the circuit interrupting assembly moves between the reset position and the tripped position such that a gap is established between the plurality of circuit interrupting contacts in the tripped state, the gap being substantially greater than or equal to a predetermined distance.	09-26-2013
20140217920	Toggle Switch And Variable Actuator Control - The present invention is directed to a device for regulating an amount of electrical power provided to at least one electrical load, the device comprising a control circuit disposed in the housing and including at least one switch device movable between a first switch state and a second switch state. The control circuit further includes a power control element that has a power control actuator configured to adjust the amount of power provided to the at least one electrical load. A variable control actuator is accessible to the user via the control aperture and coupled to the power control actuator via a linkage structure. The linkage structure further includes a pin and channel arrangement configured to convert a user control action into a power control actuator adjustment by translating rotational motion into linear motion or linear motion into rotational motion.	08-07-2014

Patrick J. Murphy, East Aurora, NY US

Patent application number	Description	Published
20100037440	Attachment System for Entertainment Device - The present invention relates to an attachment system or mounting structure that can be used with a device to mount or couple the device to a support, such as an infant support structure. In different embodiments, the device can be an entertainment device, such as a mobile or toy aquarium, or another type of device, such as a monitor. In different embodiments, the infant support structure can be a crib or bassinet or other type of structure.	02-18-2010
20100323581	Mobile for Infant Support Structure - A mobile mountable to an infant support structure includes a housing having a drive mechanism, a support arm extending from the housing, and an assembly supported from the support arm. The support arm is connected to the drive mechanism and movable relative to the housing in first and second opposite directions. The assembly includes a hub, a motion portion, and a hanging portion. The motion portion has a resilient component coupled to the hanging portion, which drives the hanging portion in a third direction when the support arm moves in the first direction.	12-23-2010

Paul Murphy, Brooklyn, NY US

Patent application number	Description	Published
20140041006	SECURE MESSAGING CENTER - A secure messaging system is disclosed wherein messages are transmitted to a user based on a feature unique to the user, such as an account number. The user authenticates himself, then messages associated with the user can be displayed.	02-06-2014

Paul Murphy, Rochester, NY US

Patent application number	Description	Published
20090251702	Stitching of near-nulled subaperture measurements - A metrology system for measuring aspheric test objects by subaperture stitching. A wavefront-measuring gauge having a limited capture range of wavefront shapes collects partially overlapping subaperture measurements over the test object. A variable optical aberrator reshapes the measurement wavefront with between a limited number of the measurements to maintain the measurement wavefront within the capture range of the wavefront-measuring gauge. Various error compensators are incorporated into a stitching operation to manage residual errors associated with the use of the variable optical aberrator.	10-08-2009
20140152999	INTEGRATED WAVEFRONT SENSOR AND PROFILOMETER - An instrument for measuring aspheric optical surfaces includes both an optical wavefront sensor and a single-point optical profilometer. The optical wavefront sensor measures surface height variations throughout one or more areas of an aspheric test surface. The single-point profilometer measures surface height variations along one or more traces on the aspheric test surface. At least one of the traces intersects at least one of the areas, and respective spatial frames of reference for the traces and areas are relatively adapted to each other by minimizing differences between points of nominal coincidence between the areas and traces.	06-05-2014

Peter J. Murphy, Huntington, NY US

Patent application number	Description	Published
20080291687	Optical filter assembly and method - A filter assembly includes a mounting element for receiving and mounting on a forward portion of a headlight, and a central opening, and a frame rotatably coupled to the mounting element, the frame having an optical filter for selectively blocking wavelengths below a first limit from the optical path between the source and the output. The frame is rotatable between a closed position in which the filter substantially covers the central opening of the mounting element, and an open position in which the central opening of the mounting element is substantially open. Both the mounting element and the frame have a central axis through their respective openings, which axis is substantially the central axis of light being emitted from a headlight when the filter assembly is mounted on a headlight.	11-27-2008

Peter John Murphy, Schenectady, NY US

Patent application number	Description	Published
20120285227	METHOD FOR DETERMINING STEAMPATH EFFICIENCY OF A STEAM TURBINE SECTION WITH INTERNAL LEAKAGE - A method of more accurately measuring steam turbine efficiency is disclosed in which the sealing steam in the steam turbine is re-routed so that a more accurate measure of steam turbine efficiency can be made. Some of the steam entering a turbine goes into the turbine's end pack and then mixes with the steam that goes through the turbine. Piping is added from one of the end pack line's to the condenser. This added line has a valve, pressure, temperature and flow measuring devices. As the valve is opened, the amount of flow going to the end pack line allowing the end pack steam mix with the steam that goes through the turbine is reduced. As the flow in this line is reduced the measured temperature at the turbine exhaust will also decrease. The amount that the valve is opened is increased until either the exhaust temperature has reached a minimum, or the enthalpy in the pipe changes from the initial enthalpy.	11-15-2012
20130243565	STEAM TURBINE AND METHOD FOR REMOVING MOISTURE FROM THE STEAM TURBINE - A steam turbine includes an inner casing that at least partially defines the steam flow path, a passage for extending through the inner casing to at least partially define a moisture flow path out of the steam flow path, and a seal operably connected to the passage. The seal has a first position associated with a first set of operating conditions within the steam flow path and a second position associated with a second set of operating conditions within the steam flow path.	09-19-2013

Randolph C. Murphy, Ithaca, NY US

Patent application number	Description	Published
20090100644	BELT WITH DEPENDENT STRAP LOOPS FOR RECEIVING PINCHERS - The present invention broadly comprises a support belt having a band including a first end having a fastener, a second end configured to receive the fastener and a middle portion having a midpoint and arranged between the first and second ends. The present invention also includes a first dependent loop coupled to the first end of the band and a second dependent loop coupled to the second end of the band, wherein the first and second dependent loops are disposed at a predetermined angle to the band.	04-23-2009

Richard J. Murphy, Clinton Corners, NY US

Patent application number	Description	Published
20100009502	Semiconductor Fabrication Process Including An SiGe Rework Method - A method for fabricating a semiconductor device includes forming an SiGe region. The SiGe region can be an embedded source and drain region, or a compressive SiGe channel layer, or other SiGe regions within a semiconductor device. The SiGe region is exposed to an SC1 solution and excess surface portions of the SiGe region are selectively removed. The SC1 etching process can be part of a rework method in which overgrowth regions of SiGe are selectively removed by exposing the SiGe to and SC1 solution maintained at an elevated temperature. The etching process is carried out for a period of time sufficient to remove excess surface portions of SiGe. The SC1 etching process can be carried out at elevated temperatures ranging from about 25° C. to about 65° C.	01-14-2010

Richard John Murphy, Hopewell Junction, NY US

Patent application number	Description	Published
20120094498	METHOD FOR REDUCING PUNCH-THROUGH DEFECTS - A method for reducing punch-through defects during semiconductor fabrication is disclosed. Various parameters such as partial pressure, total pressure, and temperature are manipulated to reduce punch-through defects, while still maintaining an acceptable etch rate. Some embodiments of the present invention also comprise the use of precursors, such as germane, to achieve faster etch rates with lower etch temperatures.	04-19-2012

Robert L. Murphy, Somers, NY US

Patent application number	Description	Published
20140151397	ENHANCED DISPENSING AND DOSAGING TECHNIQUES FOR FLUID CONTAINERS - In various embodiments, the invention provides enhanced structures, devices, and techniques that allow fluids and liquid products, such as cosmetics, to dispense in a more even, smoother, and more predictable manner from fluid containers.	06-05-2014
20140151398	ENHANCED DISPENSING AND DOSAGING TECHNIQUES FOR FLUID CONTAINERS - In various embodiments, the invention provides enhanced structures, devices, and techniques that allow fluids and liquid products, such as cosmetics, to dispense in a more even, smoother, and more predictable manner from fluid containers.	06-05-2014
20140151399	ENHANCED DISPENSING AND DOSAGING TECHNIQUES FOR FLUID CONTAINERS - In various embodiments, the invention provides enhanced structures, devices, and techniques that allow fluids and liquid products, such as cosmetics, to dispense in a more even, smoother, and more predictable manner from fluid containers.	06-05-2014
20140151400	ENHANCED DISPENSING AND DOSAGING TECHNIQUES FOR FLUID CONTAINERS - In various embodiments, the invention provides enhanced structures, devices, and techniques that allow fluids and liquid products, such as cosmetics, to dispense in a more even, smoother, and more predictable manner from fluid containers.	06-05-2014
20140151401	ENHANCED DISPENSING AND DOSAGING TECHNIQUES FOR FLUID CONTAINERS - In various embodiments, the invention provides enhanced structures, devices, and techniques that allow fluids and liquid products, such as cosmetics, to dispense in a more even, smoother, and more predictable manner from fluid containers.	06-05-2014
20140151406	ENHANCED DISPENSING AND DOSAGING TECHNIQUES FOR FLUID CONTAINERS - In various embodiments, the invention provides enhanced structures, devices, and techniques that allow fluids and liquid products, such as cosmetics, to dispense in a more even, smoother, and more predictable manner from fluid containers.	06-05-2014
20140151409	ENHANCED DISPENSING AND DOSAGING TECHNIQUES FOR FLUID CONTAINERS - In various embodiments, the invention provides enhanced structures, devices, and techniques that allow fluids and liquid products, such as cosmetics, to dispense in a more even, smoother, and more predictable manner from fluid containers.	06-05-2014

Ryan Murphy, New York, NY US

Patent application number	Description	Published
20130140498	SYSTEMS AND METHODS FOR DISPERSING GRAPHITIC CARBON - Methods and systems for improved dispersion and solubility of carbon materials such as carbon nanotubes through novel binary solvent blends, which include in some embodiments, a mixture of a dibasic ester blend and DMSO.	06-06-2013

Thomas E. Murphy, Vestal, NY US

Patent application number	Description	Published
20090307316	MINIMIZING INCORRECTLY ADDRESSED COMMUNICATIONS WHEN WORKING WITH AMBIGUOUS RECIPIENT DESIGNATIONS - Sending communications to incorrect recipients is minimized. Recipients that have ambiguous names or other designations are marked as ambiguous. Then, in response to including one of those names or designations in a communication, the originator of the communication is automatically warned of the ambiguity. This enables the originator to re-confirm that the communication is being sent to the intended recipient.	12-10-2009
20140380297	HYPERVISOR SUBPARTITION AS CONCURRENT UPGRADE - A processor-implemented method for a concurrent software service upgrade is provided. The processor implemented method may include receiving a type of service request corresponding to the software service upgrade, determining, by the processor, the type of service request and then generating a plurality of subpartitions corresponding to a hypervisor. The method may further include applying the service request to at least one subpartition within the plurality of subpartitions, wherein the service request is applied to the at least one subpartition based on the type of service request and balancing the system resources among the plurality of subpartitions upon the applying of the service request to the at least one subpartition.	12-25-2014

Thomas E. Murphy, Hopewell Junction, NY US

Patent application number	Description	Published
20080201146	METHOD, SYSTEM AND PROGRAM PRODUCT USED IN CONJUNCTION WITH VOICE RECOGNITION APPLICATIONS - A system, method and program product for the shortcomings of the prior art are overcome and additional advantages are provided through a system, method and program product for initializing a speech recognition application for a computer. The method comprises recording a variety of sounds associated with a specific text; identifying location of different words as pronounced in different locations of this recorded specific text; and calibrating word location of an input stream based on results of the pre-recorded and identified word locations when attempting to parse words received from spoken sentences of the input stream.	08-21-2008

Tim Murphy, New York, NY US

Patent application number	Description	Published
20110274173	Video compression and encoding method - A method of compressing video data having at least one frame having at least one block and each block having an array of pixels is provided. The method transforms the pixels of each block into coefficients and creates an optimal transmission order of the coefficients. The method also optimizes the speed of processing compressed video data by partitioning the data bitstream and coding each partition independently. The method also predicts fractional pixel motion by selecting an interpolation method for each given plurality or block of pixels depending upon at least one metric related to each given block and varies the method from block to block. The method also enhances error recovery for a current frame using a frame prior to the frame immediately before the current frame as the only reference frame for lessening quality loss during data transmission. Enhanced motion vector coding is also provided.	11-10-2011
20120020411	VIDEO COMPRESSION AND ENCODING METHOD - Disclosed herein is a method for encoding a video signal having at least one frame with a plurality of blocks including a current block, including generating, for at least a selected pixel in the current block, a predicted value for at least one pixel located in a row i and a column j of the current block using a processor and according to the following equation: X	01-26-2012
20120027096	Video compression and encoding method - Disclosed herein is a method for encoding at least one video frame having a plurality of blocks including a current block, including determining motion vectors for each of at least some of blocks surrounding the current block, identifying surrounding blocks having that have the same motion vector and assigning the identified surrounding blocks to a plurality of groups, determining a number of blocks in at least two of the plurality of groups and selecting a motion vector to encode the current block based on the determined number of blocks in the at least two groups.	02-02-2012
20130010867	VIDEO COMPRESSION AND ENCODING METHOD - Disclosed herein is a method for decoding a video signal having at least one frame with a plurality of blocks including a current block, including generating, for at least a selected pixel in the current block, a predicted value for at least one pixel located in a row i and a column j of the current block using a processor and according to the following equation: X	01-10-2013
20130010868	VIDEO COMPRESSION AND ENCODING METHOD - Disclosed herein is a method for decoding a video signal having at least one frame with a plurality of blocks including a current block, including generating, for at least a selected pixel in the current block, a predicted value for at least one pixel located in a row i and a column j of the current block using a processor and according to the following equation: X	01-10-2013
20130016778	VIDEO COMPRESSION AND ENCODING METHOD - Disclosed herein is a method for decoding a video signal having at least one frame with a plurality of blocks including a current block, including generating, for at least a selected pixel in the current block, a predicted value for at least one pixel located in a row i and a column j of the current block using a processor and according to the following equation: X	01-17-2013
20130016779	VIDEO COMPRESSION AND ENCODING METHOD - Disclosed herein is a method for decoding a video signal having at least one frame with a plurality of blocks including a current block, including generating, for at least a selected pixel in the current block, a predicted value for at least one pixel located in a row i and a column j of the current block using a processor and according to the following equation: X	01-17-2013

Timothy F. Murphy, E. Amherst, NY US

Patent application number	Description	Published
20090169577	METHOD FOR STIMULATING IMMUNE RESPONSE AGAINST MORAXELLA CATARRHALIS - Provided is a method for stimulating in an individual an immune response against	07-02-2009

Timothy F. Murphy, East Amherst, NY US

Patent application number	Description	Published
20090092629	VACCINE FOR NONTYPEABLE HAEMOPHILUS INFLUENZAE INFECTION - This invention provides a method for identifying strains of nontypeable	04-09-2009
20130129765	Compositions and Methods for Stimulating Immune Response Against Moraxella Catarrhalis - This invention provides a method for stimulating in an individual an immune response against	05-23-2013

Timothy J. Murphy, Massapequa, NY US

Patent application number	Description	Published
20100127498	STEAM DRIVEN TURBINE GENERATOR SYSTEM - A system for generating electricity from steam power, which includes a steam source communicated with a steam load, the steam load requiring steam at a load pressure lower than the steam source; a pressure reduction valve communicated between the steam source and the steam load, and adapted to reduce steam pressure to the load pressure; and a pressure reduction valve bypass circuit including a steam turbine for converting steam to electric power, the turbine being communicated with an electric power load to provide power to the load. The turbine is advantageously positioned vertically above a motor.	05-27-2010

William Murphy, New York, NY US

Patent application number	Description	Published
20100280972	System and Method for Locating a Document Containing a Selected Number and Displaying the Number as it Appears in the Document - The disclosure describes a system and method for locating a number in a source document by presenting and manipulating data on private and public companies. A central database of financial information is established. A target entity is entered within the central database by a user, and financial information of the target entity from the central database is displayed. Once a number within the display of financial information is selected, the system and method determines which document is the source document containing the numbers, searches through the source document for the number, identifies the location of the number in the source document and highlights and displays the number as it appears in the source document to the user.	11-04-2010
20110082857	SYSTEM AND METHOD FOR LOCATING A SELECTED NUMBER AND DISPLAYING THE NUMBER AS IT APPEARS IN A DOCUMENT CONTAINING THE NUMBER - The disclosure describes a system and method for locating a number in a source document by presenting and manipulating data on private and public companies. A central database of financial information is established. A target entity is entered within the central database by a user, and financial information of the target entity from the central database is displayed. Once a number within the display of financial information is selected, the system and method determines which document is the source document containing the numbers, searches through the source document for the number, identifies the location of the number in the source document and highlights and displays the number as it appears in the source document to the user.	04-07-2011

William E. Murphy, Vestal, NY US

Patent application number	Description	Published
20090267227	PLASTIC BALL GRID ARRAY RUGGEDIZATION - A method and product which provides a thin metal or ceramic plate to the top of a plastic grid array (PGA) as a stiffener to maintain its flatness over temperature during a column attach process, and the columns are used for attachment to circuit boards or other circuit devices. These may be constructed in this manner initially or may be retrofitted plastic ball grid arrays from which the solder balls are removed and, the stiffener is attached to the top, and the solder columns have been added to replace the solder balls. The stiffener is a bonded thin metal or ceramic plate attached to the top of the PGA to maintain its flatness over temperature during the column attach process. An aluminum plate bonded to the top of a PGA results in a significant reduction in warping during a temperature cycle. This allows attachment of solder columns to the PBGA. The high melt solder columns are attached to an area array pattern on the PBGA substrate. This array is typically either a solid or perimeter grid. It is critical that the ends of the solder columns opposite the ends attached to the substrate align precisely with the matching grid of solder pads on the printed wiring board. The purpose of the stiffening plate is to maintain the flatness of the PBGA during the process of attaching the columns to the substrate as well as attaching the component to the printed wiring board such that the columns maintain their alignment over this temperature range.	10-29-2009